期刊文献+

药源性特异质肝损伤及其发生机制的研究进展 被引量:7

Advances in Researches on Idiosyncratic Drug Induced Liver Injury and Its Occurrence Mechanism
原文传递
导出
摘要 药源性特异质肝损伤是一种在临床剂量范围内,仅在少数病人身上发生的药物不良反应。由于难以预测,特异质肝损伤带来的危害相对于传统肝损伤来说更为严重,对其产生原因及损伤机制的了解有助于临床的安全用药。综述特异质肝损伤的发生机制及目前采用的研究方法,以为其预防和治疗提供思路。 Idiosyncratic drug induced liver injury(IDILI) is a unique kind of adverse drug reaction,which only happens on a smaller number of patients who take the drug under the clinical dosage.Due to the difficulty of predicting,the damage of IDILI is much more serious than that of the traditional drug liver injury.The occurrence mechanism of IDILI and its research methods were reviewed so as to provide thoughts on the prevention and treatment of idiosyncratic liver injury.
出处 《药学进展》 CAS 2012年第12期546-551,共6页 Progress in Pharmaceutical Sciences
基金 中医药行业科研专项(No.200707008)
关键词 特异质肝损伤 药物不良反应 发生机制 实验模型 idiosyncratic liver injury adverse drug reaction occurrence mechanism experiment model
  • 相关文献

参考文献30

  • 1Frank R, Hargreaves R. Clinical biomarkers in drug dis- covery and development[ J]. Nat Rev Drttg Discov ,2003, 2(7) :566-580.
  • 2Lasser K E, Allen P D, Woolhandler S J, et al. Timing of new black box warnings and withdrawals for prescription medications[ J]. JAMA ,2002,287 ( 17 ) :2215-2220.
  • 3Thames G. Drug-induced liver injury: what you need to know [ J ]. Gastroenterol Nuts, 2004,27 ( 1 ) : 31-33.
  • 4Stickel F,Patsenker E,Schuppan D. Herbal hepatotoxicity [J]. J Hepatol,2005,43 (5) :901-910.
  • 5Ostapowicz G,Fontana R J, Schiodt F V,et al. Results of a prospective study of aeute liver failure at 17 tertiary care centers in the United States [ J ]. Ann Intern Med, 2002, 137(12) :947-954.
  • 6Ju C, Reilly T. Role of immune reactions in drug-indueed liver injury (DILI ) [ J ]. Drug Metab Rev, 2012,44 ( 1 ) : 107-115.
  • 7Lee W M. Drug-indueed hepatotoxieity [ J ]. N Engl J Med,2003,349 ( 20 ) :474 -485.
  • 8Uetrecht J. Idiosyncratie drug reactions: current under- standing [ J ]. Annu Rev Pharmaeol Toxieol, 2007,47 ( 7 ) : 513-539.
  • 9Pasipanodya J G, Gumbo T. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepato- toxic than the low doses currently used [ J ]. Antimicrob Agents Chemother ,2010 ,54( 7 ) :2847-2854.
  • 10Chalasani N, Bjtirnsson E. Risk factors for idiosyneratie drug-induced liver injury [ J ]. Gastroenterology, 2010,138( 7 ) : 2246-2259.

同被引文献198

引证文献7

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部